Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $158.44 +0.74 (+0.47%) Closing price 04:00 PM EasternExtended Trading$157.68 -0.76 (-0.48%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Natera Stock (NASDAQ:NTRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Natera alerts:Sign Up Key Stats Today's Range$152.62▼$158.5050-Day Range$133.66▼$171.8752-Week Range$110.57▼$183.00Volume714,125 shsAverage Volume1.53 million shsMarket Capitalization$21.75 billionP/E RatioN/ADividend YieldN/APrice Target$193.87Consensus RatingBuy Company Overview Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. Read More Natera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreNTRA MarketRank™: Natera scored higher than 64% of companies evaluated by MarketBeat, and ranked 266th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.49) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -82.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -82.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 17.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.07% of the float of Natera has been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Natera has recently increased by 6.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.07% of the float of Natera has been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Natera has recently increased by 6.72%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.85 News SentimentNatera has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 44 news articles for Natera this week, compared to 20 articles on an average week.Search Interest24 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 2,300% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,986,542.00 in company stock.Percentage Held by InsidersOnly 5.63% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Stock News HeadlinesGail Boxer Marcus Sells 2,496 Shares of Natera, Inc. (NASDAQ:NTRA) StockAugust 6, 2025 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 1,710 Shares of StockJuly 31, 2025 | insidertrades.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 14 at 2:00 AM | Brownstone Research (Ad)Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 495 Shares of StockJuly 25, 2025 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 291 Shares of StockJuly 23, 2025 | insidertrades.com5 Revealing Analyst Questions From Natera’s Q2 Earnings CallAugust 14 at 11:47 AM | finance.yahoo.comRep. Josh Gottheimer Sells Natera, Inc. (NASDAQ:NTRA) StockAugust 14 at 2:42 AM | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives $192.53 Average Price Target from AnalystsAugust 14 at 2:07 AM | americanbankingnews.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $158.30 on January 1st, 2025. Since then, NTRA stock has decreased by 0.3% and is now trading at $157.7640. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Thursday, August, 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. Natera's quarterly revenue was up 32.2% compared to the same quarter last year. Read the conference call transcript. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's top institutional investors include Vanguard Group Inc. (9.28%), JPMorgan Chase & Co. (7.78%), State Street Corp (2.42%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, John Fesko, Solomon Moshkevich, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Rowan E Chapman, Gail Boxer Marcus and Robert Alan Schueren. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/07/2025Today8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees4,434Year FoundedN/APrice Target and Rating Average Price Target for Natera$193.87 High Price Target$255.00 Low Price Target$150.00 Potential Upside/Downside+22.8%Consensus RatingBuy Rating Score (0-4)3.06 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.43 million Net Margins-12.89% Pretax Margin-12.90% Return on Equity-22.22% Return on Assets-15.03% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.74 Sales & Book Value Annual Sales$1.70 billion Price / Sales12.77 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book17.39Miscellaneous Outstanding Shares137,250,000Free Float129,521,000Market Cap$21.67 billion OptionableOptionable Beta1.76 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NTRA) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.